Rankings / Longevity — Peptides
Epithalon (epitalon)
Longevity · Pineal peptide bioregulator
Tier C+
Bottom line
Read Off Label grades Epithalon (epitalon) as C+ (5.3/10) based on preclinical evidence, variable benefit magnitude, and a low-risk safety profile.
Most data from Khavinson's Russian St.
Studied, labeled, or reported-use context: 5-10 mg SC/IM daily for 10-20 day courses, 1-2x/year — Research chemical; PCAC voted 7-5 (one abstention) in favour of adding epitalon to the 503A bulks list, for insomnia (Jul 23-24, 2026) — advisory only, not an FDA approval or a final compounding decision; not individualized guidance.
Frontier potential — editorial judgment, not evidence
This is a separate axis from the grade above. It asks a different question: if this worked in humans, how much would it matter? It is our judgment, it is not part of the composite score, and it cannot raise a grade. A high number here is a statement about the idea, not about whether it works or whether anyone should take it.
What the ceiling rests on
A long Russian clinical tradition reports mortality and functional benefits, and there is a proposed telomerase-activation mechanism.
Why it may not get there
Essentially the entire evidence base comes from one institute, largely outside Western peer review, with trial designs and data that have not been independently verified. Telomerase activation is not obviously desirable — it is a recognised cancer-risk pathway, and no long-term oncological follow-up exists. The mechanism is asserted more than demonstrated.
What would change this Independent replication outside the originating research tradition.
If you were testing this on yourself
Two properties decide whether an n-of-1 experiment is readable and recoverable. These describe the experiment — they are not a judgment about whether to run it, and nothing here is a recommendation.
Can you undo it?
Slow to reverse
Short peptide exposure, but the proposed mechanism is telomerase activation — a recognised cancer-risk pathway with no long-term follow-up in humans. A theoretical oncological risk is not something stopping resolves.
Can you tell if it worked?
Nothing you can measure
No endpoint exists that you could observe for the reason this is taken. An experiment without a readout cannot tell you anything, however it turns out.
What would fool you No endpoint exists that a person could read. Telomere-length testing is commercially available, highly variable between labs, and not established as meaning anything about health outcomes.
What the evidence says
Most data from Khavinson's Russian St. Petersburg Institute — limited Western peer-review. Claims of telomere lengthening in somatic cells. Interesting hypothesis but long-term cancer risk from telomerase activation unexamined. The FDA Pharmacy Compounding Advisory Committee (PCAC) met Jul 23-24, 2026 and voted on seven peptides for the 503A bulk drug substances list. Committee votes are advisory: the FDA is not bound by them, adding a substance to the 503A list would follow notice-and-comment rulemaking, and inclusion would permit compounding — it would not constitute FDA approval, an efficacy finding, or a safety determination. FDA's own review staff had recommended against the four Jul 23 peptides, citing poor characterization, weak human efficacy and safety evidence, and unassessed immunogenicity; press coverage also noted committee members' financial ties to the peptide industry. The underlying human evidence base for these compounds is unchanged by the vote. On this compound the committee voted 7-5 (one abstention) in favour of adding epitalon to the 503A bulks list, for insomnia.
Mechanism
Synthetic Ala-Glu-Asp-Gly tetrapeptide (Khavinson); proposed telomerase activation; pineal modulation; restoration of melatonin rhythm
Studied, labeled, or reported dose & route
5-10 mg SC/IM daily for 10-20 day courses, 1-2x/year
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Epithalon (epitalon)'s effects?
- Read Off Label rates the evidence for Epithalon (epitalon) as Preclinical and the benefit magnitude as variable, producing an overall grade of C+ (5.3/10). Most data from Khavinson's Russian St.
- What safety findings are reported for Epithalon (epitalon)?
- Epithalon (epitalon) has a low risk profile in the database. Low (reported) Legal status: Research chemical; PCAC voted 7-5 (one abstention) in favour of adding epitalon to the 503A bulks list, for insomnia (Jul 23-24, 2026) — advisory only, not an FDA approval or a final compounding decision.
- What doses or routes are reported for Epithalon (epitalon)?
- 5-10 mg SC/IM daily for 10-20 day courses, 1-2x/year This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Epithalon (epitalon) work?
- Synthetic Ala-Glu-Asp-Gly tetrapeptide (Khavinson); proposed telomerase activation; pineal modulation; restoration of melatonin rhythm
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.